ENTRY       D10527            Mixture   Drug
NAME        Acetylsalicylic acid and lansoprazole;
            Acetylsalicylic acid and lansoprazole;
            Takelda (TN)
COMPONENT   Aspirin [DR:D00109], Lansoprazole [DR:D00355]
CLASS       Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 3399
            ATC code: B01AC56
            Product: D10527<JP>
EFFICACY    Antithrombotic
COMMENT     Lansoprazole is primarily metabolized by CYP2C19 and CYP3A4.
METABOLISM  Enzyme: CYP2C19 [HSA:1557], CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B01 ANTITHROMBOTIC AGENTS
               B01A ANTITHROMBOTIC AGENTS
                B01AC Platelet aggregation inhibitors excl. heparin
                 B01AC56 Acetylsalicylic acid, combinations with proton pump inhibitors
                  D10527  Acetylsalicylic acid and lansoprazole &lt;JP&gt;
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               339  Miscellaneous
                3399  Others
                 D10527  Acetylsalicylic acid and lansoprazole
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               D10527  Acetylsalicylic acid and lansoprazole
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10527  Acetylsalicylic acid and lansoprazole
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10527
DBLINKS     PubChem: 254741489
///
